Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis

2008

Progesterone Receptor Variation and Ovarian Cancer Risk

Sample size: 12402 publication Evidence: moderate

Author Information

Author(s): Pearce C L, Wu A H, Gayther S A, Bale A E, Beck P A, Beesley J, Chanock S, Cramer D W, DiCioccio R, Edwards R, Fredericksen Z S, Garcia-Closas M, Goode E L, Green A C, Hartmann L C, Hogdall E, Kjær S K, Lissowska J, McGuire V, Modugno F, Moysich K, Ness R B, Ramus S J, Risch H A, Sellers T A, Song H, Stram D O, Terry K L, Webb P M, Whiteman D C, Whittemore A S, Zheng W, Pharoah P D P, Chenevix-Trench G, Pike M C, Schildkraut J, Berchuck A

Primary Institution: Department of Preventive Medicine, Keck School of Medicine, University of Southern California

Hypothesis

Does variation in the progesterone receptor gene influence the risk of ovarian cancer?

Conclusion

The study found that while three variants in the progesterone receptor gene are not associated with overall ovarian cancer risk, the PROGINS variant may increase the risk specifically for endometrioid ovarian cancer.

Supporting Evidence

The study included 4788 ovarian cancer cases and 7614 controls.
Statistically significant association was found between the PROGINS allele and endometrioid ovarian cancer risk.
Suggestive evidence of association was observed for the +331C/T variant with endometrioid ovarian cancer.

Takeaway

This study looked at how certain gene changes might affect the risk of getting ovarian cancer, and found that one specific change could be linked to a certain type of ovarian cancer.

Methodology

The study used unconditional logistic regression to analyze data from 12 case-control studies, examining three specific SNPs in the progesterone receptor gene.